Genomic variants in vaccine targets are a critical consideration in vaccine design, as changes in the genetic makeup of pathogens can influence vaccine effectiveness. Pathogens, such as viruses and bacteria, can undergo mutations that lead to new strains with altered characteristics, including changes in their surface proteins, which are often the targets of vaccines. These genetic variants can reduce the ability of the immune system to recognize and fight the pathogen, making existing vaccines less effective. Understanding the genomic variations of pathogens allows scientists to predict potential variants and adapt vaccine formulations accordingly. This is particularly important in the case of rapidly mutating viruses like influenza and HIV, where continuous surveillance and vaccine updates are necessary. Research into genomic variants helps ensure that vaccines remain effective against evolving pathogens, providing long-term protection and minimizing the risk of vaccine-resistant strains.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States